Saturday, November 14, 2026

USD/EUR Bearish Momentum: 0.794% Down In The Last 24 Hours

Automated market report from our archive (2020–2024), published before source-traceability. How we work

USD/EUR Bearish Momentum: 0.794% Down In The Last 24 Hours

(VIANEWS) - USD/EUR (USDEUR) has been up by 0.7937% for the last session's close. At 06:09 EST on Wednesday, 1 March, USD/EUR (USDEUR) is $0.94.

USD/EUR (USDEUR) Range

Regarding USD/EUR's daily highs and lows, it's 0.213% down from its trailing 24 hours low of $0.94 and 0.804% down from its trailing 24 hours high of $0.95.

USD/EUR's yearly highs and lows, it's 4.831% up from its 52-week low and 10.571% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was 0.26%, 0.23%, and 0.43%, respectively.

USD/EUR's highest amplitude of average volatility was 0.26% (last week), 0.47% (last month), and 0.43% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be overbought (>=80).

News about

  • According to FXStreet on Monday, 27 February, "The only thing preventing USD/JPY from continuing to retrace towards 140 is the dip in Treasury yields yesterday.''"
  • Usd/jpy: yen vulnerable to a further correction lower – MUFG. According to FXStreet on Monday, 27 February, "The recent move higher in US rates has helped to lift USD/JPY back above the 135.00level and it has continued to move closer to its' 200-Day Moving Average that comes in at around 137.10."
  • Usd/jpy price analysis: bears lurking near 136.50. According to FXStreet on Monday, 27 February, "In turn, USD/JPY rallied hard but it is now in a corrective territory as the following illustrates:"
  • Usd/jpy retraces to 136.00 as yields pull back from multi-day high, boj talks eyed. According to FXStreet on Monday, 27 February, "Other than the US data and yields, the geopolitical fears surrounding Russia and China also propel the DXY and probe the USD/JPY pair's latest weakness.", "On the other hand, strong US inflation cues and hawkish Fed concerns favored the USD/JPY buyers previously. "
  • Usd/jpy remains on the defensive below YTD peak amid softer usd, bullish potential intact. According to FXStreet on Monday, 27 February, "Traders will further take cues from the broader risk sentiment to grab short-term opportunities around the USD/JPY pair.", "A softer tone surrounding the US Treasury bond yields trigger a modest US Dollar pullback from a seven-week high, which, in turn, is seen exerting some downward pressure on the USD/JPY pair. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com